Save
esh.org
Selected Abstract: The effect of body mass Index on the safety of bosutinib in patients with chronic myeloid leukemia: a post hoc pooled data analysis
ESH eLearning, Susanne Isfort, 404242
Selected Abstract: CML-Registry (CML VI): achievement of ELN treatment milestones is predictive for deep molecular response (DMR) in real-world setting
ESH eLearning, Katharina Kohlbrenner, 404241
Keynote Presentation: CML: Have we reached the peak?
ESH eLearning, Carlo Gambacorti-Passerini, 404240
Selected Abstract: Why are not all eligible CML patients willing to attempt TKI discontinuation?
ESH eLearning, Daniela Zackova, 404238
Selected Abstract: Sensitive measurement of residual disease in granulocytes and T cells strongly predicts relapse in chronic myeloid leukaemia patients stopping therapy
ESH eLearning, Ilaria Pagani, 404237
Keynote Presentation: Are current recommendations enough or too much?
ESH eLearning, Dragana Milojkovic, 404236
From IRIS to SPIRIT toward treatment discontinuation for CML patients
ESH eLearning, François GUILHOT, 404235
Selected Abstract: Tyrosine kinase inhibitor-free remission after salvage therapy for resistance, warning or lack of deep molecular response in chronic myeloid leukemia
ESH eLearning, Delphine Rea, 404234
Selected Abstract: A successful treatment-free remission is achievable also by CML patients lacking optimal requirements
ESH eLearning, Massimiliano BONIFACIO, 404233
Selected Abstract: Treatment free remissions (TFR) in children with chronic myeloid leukemia (CML) - A prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort
ESH eLearning, Nirmalya ROY MOULIK, 404232
Selected Abstract: The European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission
ESH eLearning, François-Xavier Mahon, 404231
Keynote Presentation: TFR: How do we move forward?
ESH eLearning, Massimo Breccia, 404230
Discussion
ESH eLearning, Faculty / Presenters, 404229
Pro
ESH eLearning, Giuseppe Saglio, 404228
Not yet
ESH eLearning, Jane APPERLEY, 404227
Introduction
ESH eLearning, Pierre LANEUVILLE, 404226
Novel developments in HSC transplant, treatment of GVHD
ESH eLearning, Halvard Bönig, 404225
Selected Abstract: KIR3DL1-HLA-Bw status predict favourable achievement of treatment free remission in CML: results from the POKSTIC trial, a multicentre retrospective observational study
ESH eLearning, Hiroshi Ureshino, 404222
Selected Abstract: BCL-XL a novel biomarker for treatment failure and treatment-free remission in chronic myeloid leukaemia
ESH eLearning, Claire c.lucas@chester.ac.uk, 404221
Selected Abstract: The presence of somatic mutations prior to treatment-free remission (TFR) attempt is not associated with TFR failure following tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia patients
ESH eLearning, Dennis Kim, 404219
Keynote Presentation: Hidden signatures: harnessing the full power of biomarkers in chronic myeloid leukaemia
ESH eLearning, S. Tiong ONG, 404218
Clonal hematopoiesis
ESH eLearning, Coleman Lindsley, 404215
CD47 Targeting in myeloid malignancies
ESH eLearning, Ravi Majeti, 404214
The BCL2 family in myeloid malignancies
ESH eLearning, Caroline Heckman, 404213
TP53 mutations in myeloid malignancies
ESH eLearning, Steffen BOETTCHER, 404212
Introductory overview – concepts and challenges
ESH eLearning, Shinya Kimura, 404211
Selected Abstract: Characterization of bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
ESH eLearning, Hong Qian, 404210
Selected Abstract: Overcoming TKI-resistant CML utilizing a novel PROTAC-based BCR::ABL1 degrader
ESH eLearning, Milad ROUHIMOGHADAM, 404209
Selected Abstract: The role of G0/G1 switch gene 2 (G0S2) in lipid metabolism, differentiation, and drug resistance in chronic myeloid leukemia (CML)
ESH eLearning, Anna Eiring, 404208
Keynote Presentation: Resistance to TKI: mutations and beyond
ESH eLearning, Simona SOVERINI, 404207
Germline predisposition to hematopoietic malignancies
ESH eLearning, Lucy Godley, 404206
CML is still important and relevant
ESH eLearning, Jerry Radich, 404204
Selected Abstract: Multiomic single-cell characterization of the CD14-CD34+ stem and progenitor cell compartment in chronic myeloid leukemia
ESH eLearning, Hana Komic, 404202
Selected Abstract: SETD2/H3K36mE3 deficiency hinders proper dna damage repair and enhances clonogenic potential of chronic myeloid leukemia (CML) progenitors
ESH eLearning, Manuela Mancini, 404201
Keynote Presentation: The curious case of the leukemic stem cell: why is it so elusive?
ESH eLearning, Ravi Bhatia, 404199
Autophagy networks and cancer pathogenesis
ESH eLearning, Ivan Dikic, 404198
Excellent molecular responses and tolerance observed with frontline asciminib treatment for CP-CML: results from the ALLG CML13 ASCEND-CML study
ESH eLearning, Tim Hughes, 404197
Clonal hematopoiesis mutants detected at the time of stopping therapy in deep molecular response are significantly associated with achievement of treatment-free remission (TFR)
ESH eLearning, Susan Branford, 404194
Leukaemia exposure reduces phagocytosis and efferocytosis in Philadelphia negative bone marrow-derived macrophages
ESH eLearning, Martha ZAROU, 404193
Welcome to Mandelieu
ESH eLearning, Jorge Cortes, 404190
Combining daratumumab with CD47 blockade in T-ALL
ESH eLearning, Dennis Schewe, 391225
Precision medicine for T-ALL
ESH eLearning, Guillaume Andrieu, 391224
Precision medicine for B-cell precursor ALL
ESH eLearning, Sarah K. Tasian, 391223
Targeting T-ALL via CCR9
ESH eLearning, Paul Maciocia, 391222
Role of SCT in the era of CAR-T
ESH eLearning, Jae H. Park, 391221
How to prioritize immune interaction in B-Acute Lymphoblastic Leukemia?
ESH eLearning, André Baruchel, 391220
New antibody-based ALL therapies
ESH eLearning, Federico Lussana, 391219
Front line therapy with inotuzumab ozogamicin
ESH eLearning, Philippe Rousselot, 391218
Comprehensive profiling of leukemia drug sensitivity in pediatric vs adult ALL
ESH eLearning, Jun J. Yang, 391216
Minimal chemotherapy for good-risk childhood ALL
ESH eLearning, Stephen P. Hunger, 391215
Early T-cell precursor (ETP)-ALL
ESH eLearning, Nitin Jain, 391214
The evolution of TKI therapy in Ph+ ALL
ESH eLearning, Nicholas Short, 391211
CDX2 deregulation and UBTF::ATXN7L3 define a novel B-ALL high-risk subtype
ESH eLearning, Marie Passet, 391209
Characterizing relapse initiating cells by single-cell transcriptomics
ESH eLearning, Ronald Stam, 391208
New insights in TLX3 rearranged T-ALL
ESH eLearning, Jules Meijerink, 391207
Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis
ESH eLearning, Rathana Kim, 391206
Acute leukaemia of ambiguous lineage
ESH eLearning, Charles Mullighan, 391205
Clinical use of TKIs in Ph-like ALL patients
ESH eLearning, Stephen P. Hunger, 391204
Identifying novel combination therapies for B-ALL harboring the IgH::CRLF2 rearrangement using functional genomics tools
ESH eLearning, Takahiro Maeda, 391203
Menin inhibitors
ESH eLearning, Eytan Stein, 391198
Current therapy for KMT2A-rearranged ALL
ESH eLearning, Janine Stutterheim, 391197
The biology of KMT2A-rearranged leukaemia
ESH eLearning, Katrin Ottersbach, 391196
Conference Book (PDF)
ESH eLearning, Faculty / Presenters, 391194
Panel Discussion
ESH eLearning, Faculty / Presenters, 382687
Case-based lecture: Bone disease in multiple myeloma
ESH eLearning, Elizabeth O’Donnell, 382685
Case-based lecture: Is this myeloma kidney? A case of significantly elevated free serum light chains and kidney failure
ESH eLearning, Fredrik Schjesvold, 382684
Case-based lecture: How I treat amyloidosis
ESH eLearning, Mario Nuvolone, 382683
Interactive case: How I treat Waldenstrom's macroglobulinemia
ESH eLearning, Jorge Castillo, 382682
MM treatment in 2030
ESH eLearning, Kenneth C. Anderson, 382681
Panel Discussion
ESH eLearning, Faculty / Presenters, 382680
Case-based lecture: Role of antigen loss in CAR T cell engaging antibodies
ESH eLearning, Adam Sperling, 382679
Case-based lecture: How to predict outcome of CAR T cell and T cell Engager treated patients
ESH eLearning, Paola Neri, 382678
Case-based lecture: Bi- and trispecific antibodies
ESH eLearning, Hermann Einsele, 382677
Case-based lecture: Novel targets for CAR T cells in multiple myeloma
ESH eLearning, Maik Luu, 382676
Case-based lecture: CART in multiple myeloma
ESH eLearning, Omar Nadeem, 382675
Interactive case: How to use novel immunotherapies
ESH eLearning, Hermann Einsele, 382674
Discussion
ESH eLearning, Faculty / Presenters, 382673
No
ESH eLearning, Omar Nadeem, 382672
Yes
ESH eLearning, Noemi Puig, 382671
Introduction
ESH eLearning, K. Martin Kortüm, 382670
Interactive case: Optimal sequence at relapse
ESH eLearning, Enrique Maria Ocio San Miguel, 382667
Case-based lecture : Novel agents in relapsed multiple myeloma (Selinexor, Belantamab, Venetoclax, etc)
ESH eLearning, Michel Delforge, 382666
Case-based lecture: How to use T cell engagers in relapse multiple myeloma?
ESH eLearning, María-Victoria Mateos, 382665
Case-based lecture: How I treat first relapse
ESH eLearning, Katja Weisel, 382664
Interactive case: Relapsed multiple myeloma
ESH eLearning, Xavier Leleu, 382663
Discussion
ESH eLearning, Faculty / Presenters, 382661
No
ESH eLearning, Francesca Gay, 382660
Yes
ESH eLearning, Salomon Manier, 382659
Introduction
ESH eLearning, Hermann Einsele, 382658
Discussion
ESH eLearning, Faculty / Presenters, 382657
No
ESH eLearning, Heinz Ludwig, 382656
Yes
ESH eLearning, Noemi Puig, 382655
Introduction
ESH eLearning, María-Victoria Mateos, 382654
Panel Discussion
ESH eLearning, Faculty / Presenters, 382653
Interactive case: How I treat a high-risk MM patient in the first line
ESH eLearning, Stefan Knop, 382652
Case-based lecture: Precision medicine in multiple myeloma
ESH eLearning, Marc Raab, 382651
Case-based lecture: Should we add immunotherapy in high-risk patients?
ESH eLearning, Leo Rasche, 382650
Case-based lecture: Should the high-risk patient be treated differently?
ESH eLearning, Faith Davies, 382649
Interactive case: How I diagnose the high-risk patient
ESH eLearning, Faith Davies, 382648
Panel Discussion
ESH eLearning, Faculty / Presenters, 382647

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings